Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.17 - $9.16
Previous CloseN/A
Volume680.22K
Average Volume (3M)50.93K
Market Cap
$406.95M
Enterprise Value$1.33B
Total Cash (Recent Filing)$65.98M
Total Debt (Recent Filing)$11.41M
Price to Earnings (P/E)21.7
Beta0.82
Next Earnings
Nov 12, 2025EPS Estimate
0.09Last Dividend Ex-Date
Mar 17, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding57,505,030
10 Day Avg. Volume56,137
30 Day Avg. Volume50,927
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.26
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit17.92
Enterprise Value/Ebitda38.74
Forecast
1Y Price Target
$11.36Price Target Upside61.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKamada reported financial results above expectations, including revenues of $44.8 million, up 5% compared with one year ago, and earnings per share of $0.13, versus $0.08 in the prior year.
Strategic GrowthStrengthening the biosimilar portfolio is expected to yield significant revenue over the next five years, further diversifying its commercial offerings.
Bears Say
Operational ChallengesThere has been questions regarding the AAT program since there has been historical challenges in delivering AAT to the lungs and some investors question whether the program falls under the company's core competencies.
Profit MarginsGross margins for the quarter dipped to 42% from 45% in the prior year period, due primarily to product mix and a higher reliance on distributed product sales.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $5.17 and its highest was $9.15 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $406.95M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Nov 12, 2025 which is in 78 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Aug 13, 2025. The company reported $0.132 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.042.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of $0.2 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.09.
How many shares outstanding does Kamada have?
Kamada has 57,505,030 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.132 in its last earnings report, beating expectations of $0.09. Following the earnings report the stock price went down -1.337%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in KMDA
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.36 (61.13% Upside)
$11.36 (61.13% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.83%
12-Months-Change
Fundamentals
Return on Equity
7.44%
Trailing 12-Months
Asset Growth
4.88%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Kamada with strong revenue and EBITDA growth, increased financial guidance, and successful strategic initiatives such as biosimilar launches and plasma center expansion. However, challenges like the decrease in gross profit margin and tax rate fluctuations present areas to monitor.View all KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
$11.36
▲(61.13% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.33% Mutual Funds
5.13% Other Institutional Investors
93.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---